Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 545 across all filing types
Latest filing 2026-04-23 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：关于上海之江生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审计报告" (Special Audit Report) concerning non-operating fund occupation and other related party fund transactions of Shanghai Zhijiang Biotechnology Co., Ltd. It includes an auditor's opinion, audit scope, and detailed tables of related party transactions for the fiscal year 2025. The report is issued by a certified accounting firm and references compliance with regulatory guidelines from Chinese securities and supervisory authorities. The content is focused on audit findings and verification of specific financial data related to related party transactions, not a full annual report or general financial statement. This matches the definition of an Audit Report / Information (AR) as it is a standalone audit report with applied accounting principles and audit results, distinct from a full Annual Report (10-K) or other categories. The document length (6855 characters) and detailed audit content support this classification with high confidence. FY 2025
2026-04-23 Chinese
之江生物：2025年度独立董事述职报告（徐强国）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's background, attendance at board and committee meetings, communication with auditors, oversight of financial reports, and overall evaluation of the company's governance and compliance during the year. The content is a detailed report on the independent director's duties and activities over the fiscal year, which aligns with a management or board-related report rather than a general annual report or audit report. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is also not a proxy statement, voting results, or other categories. The document focuses on the independent director's role and management oversight, which fits best under Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2026-04-23 Chinese
之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It does not contain financial statements or analysis but provides an update on the ongoing share buyback activity. The document length is short (1479 characters) and focuses on the repurchase progress rather than a full financial report or earnings release. Therefore, it fits the category of Transaction in Own Shares (POS).
2026-04-02 Chinese
之江生物：关于自愿披露公司产品获得相关认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of product certifications obtained by Shanghai Zhijiang Bio-Technology Co., Ltd. It details the certification information, product specifics, impact on the company, and risk warnings. There is no financial data, no mention of financial results, no regulatory filings or officer certifications, and no reference to meetings or votes. The document is an announcement about product certification achievements, which is a regulatory announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-03-19 Chinese
之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase (buyback) activities. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It is not a full financial report, earnings release, or management discussion. The document length is short (1481 characters) and it provides specific updates on the share buyback program. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2026-03-03 Chinese
之江生物：2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, and asset figures. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the company's 2025 annual report. The document is relatively short (1956 characters) and serves as a quick earnings update rather than a full comprehensive annual report. This type of document is typically classified as an Earnings Release (ER) because it provides key financial highlights and performance metrics for the fiscal year but is not the full annual report (10-K). FY 2025
2026-02-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.